{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-332264","form_type":"8-K","ticker":null,"cik":"0001029142","company_name":"DYNAVAX TECHNOLOGIES CORP","filed_at":"2025-12-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.586276+00:00","generated_at":"2026-05-16T12:03:45.727606+00:00","sec_items":["1.01","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Sanofi to acquire Dynavax for $15.50/share in cash, total equity value ~$2.2B","bullets":["Sanofi to acquire Dynavax for $15.50/share cash, total equity value ~$2.2B.","Offer price represents ~39% premium to Dec 23, 2025 close and ~46% over 3-month VWAP.","Acquisition includes marketed hepatitis B vaccine HEPLISAV-B and Phase 1/2 shingles candidate Z-1018.","Transaction expected to close Q1 2026, subject to majority tender, HSR clearance, other conditions.","Dynavax board unanimously approved; officers Novack and Janssen to continue roles until close."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-332264","json":"https://secwatch.observer/filing/0001193125-25-332264.json","markdown":"https://secwatch.observer/filing/0001193125-25-332264.md","text":"https://secwatch.observer/filing/0001193125-25-332264.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1029142/000119312525332264/0001193125-25-332264-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1029142/000119312525332264/d82616d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:03:45.727606+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b3ea0692665e2957b774620111acd6ba11e22e58","claim":"DYNAVAX TECHNOLOGIES CORP entered into Agreement and Plan of Merger with Sanofi (effective 2025-12-23).","evidence_excerpt":"On December 23, 2025, Dynavax Technologies Corporation, a Delaware corporation (the “ Company ” or “ Dynavax ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Sanofi, a French soci é t é anonyme (“ Parent ”) and Samba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1029142/000119312525332264/0001193125-25-332264-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Sanofi"},{"label":"Effective","value":"2025-12-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}